Lipids and Cholesterol Archive
Reducing triglyceride levels in patients with type 2 diabetes may help them attain more optimal glycemic control.
Statin use is associated with better cortical bone characteristics in older women with osteoporosis, but results are dependent upon the potency of the statins.
The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.
Socioeconomically challenged patients with obesity and elevated cardiovascular risk may benefit from digital obesity treatment combined with health system resources.
In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.
In patients with primary hypercholesterolemia, short-term treatment with simvastatin improved the lipid profile and exerted a beneficial effect on a wide range of proatherogenic and prothrombotic parameters.
Researcher observed a much lower rate of discontinuations due to skeletal muscle events with alirocumab in the open-label extension trial compared with the double-blind parent study (3.2% vs 15.9%).
A healthy lifestyle for lowering cholesterol should be emphasized for reducing cardiovascular risk across the life course.
Icosapent Ethyl Reduces Ischemic Event Risk in Patients With Hypertriglyceridemia Despite Statin Use
The risk for the primary composite endpoint was significantly lowered by 25% among patients who received 2g of icosapent ethyl twice daily vs those who received placebo.
Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.
The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.
First-year nonadherence and discontinuation are high among older adults prescribed statins.
Early detection of lipidome characteristics could help identify the early onset of type 2 diabetes.
Statin therapy is associated with reduced mitochondrial complex II-linked respiration, and statin-induced myalgia is coupled to an increased intrinsic mitochondrial respiratory function, while intramuscular [coenzyme Q10] levels are unaltered.
There is a lack of convincing evidence for an association between statin use and noncardiovascular disease outcomes.
Hyperglycemia, obesity, and hypertriglyceridemia in type 2 diabetes are negatively related to indices of cardiovascular autonomic neuropathy.
Investigators analyze characteristics of participants with acquired partial lipodystrophy who developed severe metabolic abnormalities.
Genetic testing should become the standard of care for patients with definite or probable familial hypercholesterolemia.
A variety of underlying mechanisms may be attributed to the role of statins in preventing bone-related disorders.
Low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) ≥160 mg/dL are independently associated with increased relative risk of cardiovascular disease (CVD) mortality in a low-risk cohort.
"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.
Serum 25-hydroxyvitamin D [25(OH)D] is independently and inversely associated with total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol in children.
Nutraceuticals may offer a solution to patients who cannot tolerate statins because of severe muscle pain.
There has been a substantial increase in the percentage of patients with high cholesterol over age 60 years taking lipid-lowering medications from 2005 to 2016, but such increases have not been seen among younger patients with high cholesterol.
The relationship between circadian rhythm and sleep measures and components of metabolic syndrome in patients with bipolar disorder.
Investigators revised pooled cohort equations to improve clinical accuracy to predict risk for cardiovascular disease.
Investigators examine the effects of the PCSK9 inhibitor alirocumab in patients with recent acute coronary syndrome and diabetes.
Investigators examined cardiovascular outcomes in patients with elevated triglyceridemia and diabetes treated with statins.
To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.
Investigators sought to determine whether serum lipid levels were associated with depression in patients with psychotic disorders.
For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.
Using both public and private health insurance claims data, investigators conducted a retrospective cohort study to assess cardiovascular risk in the setting of diabetes and rheumatoid arthritis.
Statins were associated with a reduction in mortality but there was no significant difference in the composite end point with fenofibrates alone or in combination with statins.
The method of individualized treatment effect prediction of fenofibrate on major cardiovascular events risk reduction in T2D can be used to guide clinical decision-making.
Abnormal ratios of omega-6 to omega-3 fatty acids were associated with the presence of bipolar disorder and the severity and duration of major depressive disorder.
From 25% to 50% of patients discontinue statins within 6 months to 1 year of starting, and the rate increases as high as 75% after 2 years.
Multiple clinical studies have examined the efficacy of pitavastatin.
Dutasteride therapy for benign prostatic hyperlasia has been linked to elevated HbA1c and LDL cholesterol.
Patients with statin intolerance had a 36% higher rate of recurrent MI compared to those with high statin adherence.
Women experienced the same CV benefits in statin trials, despite having slightly elevated on-treatment LDL cholesterol.
Risk of both ischemic stroke and coronary heart disease was elevated with high triglycerides and low high-density lipoprotein cholesterol.
Low levels of low-density lipoprotein cholesterol appear to be well tolerated on alirocumab therapy.
Data from 14 phase 2 and 3 studies were pooled to assess the safety of lowering LDL cholesterol with alirocumab.
Too few American young adults are receiving needed statin medications, according to findings published in JAMA Cardiology.
Fenofibrate therapy may reduce cardiovascular disease (CVD) in statin-treated patients with diabetes and dyslipidemia.
Oxidized low-density lipoprotein (ox-LDL) as a proxy for oxidative stress is associated with metabolic syndrome and its components.
Healthier diets may be a factor in the ongoing decline in cholesterol levels for Americans.
Women and minorities with HIV are less frequently tested for dyslipidemia, according to a new study from IDWeek 2016.
A mean 51% reduction in LDL cholesterol was seen in the group assigned to the 300 mg dose of inclisiran.
An analysis of more than 80,000 Chinese participants found that all alcohol consumption slowed the decline of HDL cholesterol in the body.
Antihypertensive drugs and rosuvastatin did not prevent or worsen cognitive decline in those at intermediate risk for CVD.
For patients with type 1 diabetes, the correlation between PCSK9 and LDL cholesterol is only seen in the highest tertile for HbA1c.
As children age, the impact of changes in HbA1c and BMI on LDL cholesterol and non-HDL cholesterol levels increases.
Low and high levels of HDL cholesterol are linked to increased mortality risk, according to a study published in the Journal of the American College of Cardiology.
Screening for hypercholesterolemia is feasible at routine child immunization visits in primary care practices.
Statins can interact with other drugs prescribed for cardiovascular disease, but there are ways to navigate the issue.
Levels of triglycerides and HDL cholesterol are independent risk factors for chronic diabetic kidney disease in type 2 diabetes.
LDL cholesterol-lowering genetic variants are associated with increased risk of type 2 diabetes, according to a meta-analysis published in JAMA.
Blacks have increased incidence of hypertension, diabetes, and dyslipidemia but not atrial fibrillation.
Treatments other than statins also can effectively reduce cardiovascular (CV) risk, according to a review and meta-analysis published in the JAMA.
At week 52, all subgroups saw a change in levels of low-density lipoprotein cholesterol.
The researchers found larger absolute benefits for prolonged therapy and also noted that benefits outweigh rare cases of adverse events.
For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone.
For patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease, PCSK9 inhibitor use is not cost-effective.
The US Preventive Services Task Force (USPSTF) has concluded that the evidence is currently insufficient to weigh the balance of benefits and harms of screening for lipid disorders in children and adolescents (aged 20 years or younger).
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Routinely measured lipid fractions may be associated with the risk of coronary artery disease (CAD) and diabetes.
Evolocumab will now be available via the Pushtronex system™, designed to deliver 420 mg in a single dose.
Patients with heterozygous familial hypercholesterolemia have a significantly increased risk for coronary heart disease and atherosclerotic cardiovascular disease.
For children with type 1 diabetes, the negative influence of celiac disease on HDL cholesterol can be improved by adherence to a gluten-free diet.
Risk for cardiovascular events was significantly lower among patients with moderate LDL levels, compared to patients with high LDL levels.
Particulate matter may alter metabolism of glucose and lipids, especially among those with diabetes.
Increased risk for cardiovascular events and all-cause mortality were observed for patients with type 2 diabetes.
Robert Eckel, MD, discusses lipid management in the era of PCSK9 inhibitors at AACE 2016.
Heterozygous mutation carriers have lower levels of non-HDL cholesterol and reduced risk for coronary artery disease.
Cardiovascular disease risk is higher when low HDL cholesterol is accompanied by high triglycerides and LDL cholesterol.
The first generic version of Crestor (rosuvastatin calcium) tablets was recently approved by the Food and Drug Administration (FDA).
Treatment is important for primary prevention even without history of cardiovascular disease, researchers said.
Greater LDL cholesterol reductions for rosuvastatin 10 mg to 40 mg vs equal and double doses of atorvastatin and simvastatin.
Children who exhibited at least 4 unhealthy behaviors were more likely to be obese and have unfavorable cholesterol levels.
Evacetrapib did lower low-density lipoprotein cholesterol in high vascular risk patients, but did not reduce major cardiovascular events.
Having both diseases raises a patient's chances for developing diabetes.
Remnant cholesterol predicted coronary artery disease events even after adjustment for presence and extent of disease.
Adolescents with autism spectrum disorder appear to be more likely to develop the disease.
Researchers found that roughly 834 500 Americans have the inherited condition.
Two studies show carriers of the ANGPTL4 variant have better lipid levels and a lower likelihood of coronary artery disease.
Adverse effects on glucose tolerance, insulin sensitivity, blood lipids observed in Mexican-Americans.
Some clinical departments tend to undertreat when prescribing statins, according to a study published in the Journal of Clinical Pharmacy and Therapeutics.
Lipid-lowering therapy with ezetimibe plus simvastatin is associated with improved clinical outcomes, with a reduction in total primary end point events.
For patients with type 2 diabetes, a statin plus extended-release niacin lowers apolipoprotein B-48 (apoB-48) concentration compared with a statin alone.
There appears to be insufficient evidence for lipid screening in children, while the recommendations for statins varies with age and risk.
In a 10-5 vote, an FDA panel recommended against expanding indications for ezetimibe and ezetimibe/simvastatin.
Follicle-stimulating hormone may interact with its receptors and lead to elevated LDL cholesterol in postmenopausal women.
Researchers noted an improvement in lipid profile for nutraceuticals alone or in combination in statin-intolerant patients.
American Academy of Pediatrics guidelines reflect concerns about obesity, suicide, and more.
Simvastatin plus ezetimibe is linked to lower risk for cataract development vs placebo.
Only half of those who should be using medications to lower cholesterol actually are.
Adults aged 40 to 59 years did not achieve Healthy People 2020 goals during 2011 to 2014.
Rosuvastatin may be more effective than atorvastatin for reversion of coronary atherosclerotic plaques.
LDL cholesterol and HbA1c goals were maintained after veterans with type 2 diabetes were discharged from pharmacist-managed clinic.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Insulin Analogs vs Regular Human Insulin for Type 2 Diabetes
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Trends in Bisphosphonate Use and Hip Fracture Rates in Denmark
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners